ADA Standards of Care in Diabetes 2024: A Guideline Topline
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
The ADA endorses 3 different measures of glycemic control to assess prediabetes and type 2 diabetes.
Screening recommendations for type 2 diabetes include adults of any age with overweight or obesity and for other adults, begin screening at age 35.
The ADA 2024 Standards of Care in Diabetes amended language throughout the section on weight management to be person-centered and to focus on weight management in the overall context of treatment for type 2 diabetes.
ADA recommends referral of adults with overweight or obesity at high risk for T2D for intensive life-style behavior change program.
Any of the established approaches to treatment of obesity can be considered in people with obesity and diabetes alone or in combination.
Although no medications are approved to prevent type 2 diabetes, the ADA recommends considering treatment with metformin for adult populations at high risk.
The ADA provides guidance for clinicians who are considering recommending metformin to individuals at high risk for type 2 diabetes.
The ADA 2024 Standards of Care in Diabetes now recommend GLP-1 and dual GLP-1/GIP receptor agonists as preferred pharmacotherapy for obesity management in people with type 2 diabetes.
The ADA preferred pharmacotherapy for those with type 2 diabetes and overweight or obesity includes GLP-1 and dual GLP-1/GIP receptor agonists, in addition to lifestyle changes.
The ADA offers guidance for clinicians who are considering prescribing GLP-1 and dual GLP-1/ GIP agonists for treatment of obesity in people with type 2 diabetes.
The ADA has expanded recommendations pertaining to weight management treatment to acknowledge the expected range of benefits across the spectrum of weight loss.
The ADA 2024 Standards of Care in Diabetes state that people with diabetes and overweight or obesity may benefit from any magnitude of weight loss.
The ADA provides recommendations for clinicians on ways to prevent clinical inertia when weight loss goals are not met in people with type 2 diabetes.
The ADA recommends evaluating individuals with type 2 diabetes and overweight or obesity for use of common medications associated with weight gain.
The ADA provides recommendations on how to include telehealth and digital interventions for diabetes self-management education and support.
The variety of digital health options to support prevention of type 2 diabetes and optimal outcomes for those with the disorder continues to expand and the ADA offers guidance on incorporating them into patient care.
The Standards of Care in Diabetes from the American Diabetes Association (ADA) is updated annually to reflect advances in therapeutics and technology and to include shifts in focus or emphasis in the clinical management of type 2 diabetes (T2D). Strategies for diagnosing diabetes are coupled with methods to prevent or delay T2D onset and its associated comorbidities.
Among updates to the 2024 iteration of the guidelines are recommendations for use of new classes of antiobesity drugs and on overall management of obesity in people with diabetes, including reducing "therapeutic inertia", providing more personalized approaches, and evaluating additional measures of obesity than body mass index (BMI).
The ADA updated Standards also encourage health care providers to become familiar with new diabetes technology, and to embrace telehealth and digital tools for diabetes self-management education.
The Guideline Topline slide show above does not cover the entire Standards document but instead offers a snapshot of numerous recommendations that may help improve outcomes in primary care.
